Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Exclusion Criteria

• •1. Accompanied by cerebral hemorrhage；
• •2. Pregnancy；
• •3. Have a mental illness or other condition that cannot proceed as planned；
• •4. Severe arrhythmia, abnormal ECG (QT\>500ms).
• •Early withdrawal from test criteria：
• •Participants have the right to withdraw from the study at any time from the trial. Exit Criteria:
• •1. The subject or the subject's legally authorized representative requests to withdraw from the study;
• •2. Participant loss to follow-up.
• •Doctor/Investigator required subjects to terminate the trial early:
• •1. Subjects who are unable to carry out follow-up treatment due to adverse events (serious irreversible organ function damage during treatment) who are judged by the investigator to be unsuitable for continuing the research;
• •2. The subject does not adhere to the protocol, such as the use of chemotherapy drugs, etc., which affects the effectiveness and safety judgment.
• •For participants who withdrew early from the study (except subjects who were lost to follow-up), the reason for their early withdrawal should be recorded, and the time of the last study's medication/treatment should be recorded, and the examination items at the time of early withdrawal from the study should be completed at the last visit, if possible.